BioSpace News Archive

TC BioPharm PLC announced that the MHRA has officially accepted its proposed amendment to the Company’s clinical trial authorisation.

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) today announced that Shawn Lu has stepped down from the Board of Directors

Astellas Pharma Inc. Chief Commercial Officer Claus Zieler has named Michael Petroutsas as Head, United States Commercial, leading the Astellas Pharma US Inc. organization.

Vivera Pharmaceuticals Inc., a leader in medical technology, biotech and biopharma, has bolstered its management team by adding Kent Barkouras as Chief Commercial Officer, the company announced.

Rejuvenate Bio today announced publication of groundbreaking research in the peer-reviewed journal Cellular Reprogramming.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2023 financial results and corporate highlights.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS and multiple sclerosis, reported new, significant survival results from two independent analyses of the pooled data from the intermediate-size EAPs supported by Clene.

AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.

CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that it will be highlighting the new Veradigm Payer Insights solution at the ViVE 2024 conference in Los Angeles, CA, Feb 25-28.